Quick Answer
ENDRA Life Sciences Inc. reported Total Revenue of $0.00 for fiscal year 2020.
ENDRA Life Sciences Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | $0.00 |
| Net Income | -$7.03M +38.9% |
-$11.51M -14.4% |
-$10.06M +23.7% |
-$13.18M -17.3% |
-$11.23M +4.2% |
-$11.73M +11.9% |
| Diluted EPS | -$8.93 +84.3% |
-$56.94 +97.9% |
-$2766.85 | — | — | — |
| Total Assets | $3.85M -13.4% |
$4.45M -34.1% |
$6.75M -27.2% |
$9.27M -28.0% |
$12.87M +46.9% |
$8.76M +22.1% |
| Long-Term Debt | — | $0.00 | $0.00 | $0.00 -100.0% |
$546.6K | — |
| Stockholders Equity | $2.26M -11.7% |
$2.56M -54.8% |
$5.66M -21.5% |
$7.20M -33.2% |
$10.78M +50.4% |
$7.17M +50.6% |
| R&D Expense | $1.85M -42.0% |
$3.19M -36.2% |
$5.00M -23.7% |
$6.55M +19.5% |
$5.48M -7.4% |
$5.92M -10.0% |
| Operating Income | -$5.76M +46.7% |
-$10.82M -2.8% |
-$10.52M +20.0% |
-$13.16M -14.4% |
-$11.50M +0.0% |
-$11.50M -6.1% |
| Gross Profit | — | — | — | — | — | $0.00 |
| Shares Outstanding | 1.18M +119.1% |
536,908 +8943.4% |
5,937 -99.8% |
3.17M +48.9% |
2.13M -93.8% |
34.05M +304.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2019 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$1.60M | +32.2% | -30.2% |
| Diluted EPS | September 30, 2025 | -$2.10 | +78.0% | +78.0% |
| Total Assets | September 30, 2025 | $1.96M | — | -30.0% |
| Cash and Equivalents | June 30, 2023 | $4.82M | — | +104.6% |
| Long-Term Debt | March 31, 2024 | $0.00 | -100.0% | — |
| Stockholders Equity | September 30, 2025 | $171.4K | -97.4% | -88.4% |
| R&D Expense | September 30, 2025 | $432.1K | -45.6% | -45.6% |
| Operating Income | September 30, 2025 | -$1.37M | +9.2% | -5.4% |
| Gross Profit | September 30, 2019 | $0.00 | — | — |
| Shares Outstanding | September 30, 2025 | 786,902 | — | +4.6% |
- ENDRA Life Sciences Inc. reported Total Revenue of $0.00 for fiscal year 2020.
- ENDRA Life Sciences Inc. reported Net Income of -$7.03 million for fiscal year 2025.
- ENDRA Life Sciences Inc. showed an increase of +38.9% in Net Income compared to the prior fiscal year.
- ENDRA Life Sciences Inc. reported Diluted EPS of $8.93 per share (loss) for fiscal year 2025.
- ENDRA Life Sciences Inc. showed an increase of +84.3% in Diluted EPS compared to the prior fiscal year.
- ENDRA Life Sciences Inc. reported Total Assets of $3.85 million for fiscal year 2025.
- ENDRA Life Sciences Inc. showed a decrease of -13.4% in Total Assets compared to the prior fiscal year.
- ENDRA Life Sciences Inc. reported Long-Term Debt of $0.00 for fiscal year 2024.
- ENDRA Life Sciences Inc. reported Stockholders Equity of $2.26 million for fiscal year 2025.
- ENDRA Life Sciences Inc. showed a decrease of -11.7% in Stockholders Equity compared to the prior fiscal year.
- ENDRA Life Sciences Inc. reported R&D Expense of $1.85 million for fiscal year 2025.
- ENDRA Life Sciences Inc. showed a decrease of -42.0% in R&D Expense compared to the prior fiscal year.
- ENDRA Life Sciences Inc. reported Operating Income of -$5.76 million for fiscal year 2025.
- ENDRA Life Sciences Inc. showed an increase of +46.7% in Operating Income compared to the prior fiscal year.
- ENDRA Life Sciences Inc. reported Gross Profit of $0.00 for fiscal year 2020.
- ENDRA Life Sciences Inc. reported Shares Outstanding of 1.18 million shares for fiscal year 2025.
- ENDRA Life Sciences Inc. showed an increase of +119.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: